Pharma Industry News
Printable Version   Email to a friend

Lopinavir Shows Promise in Preventing Cervical Cancer

August 30, 2006

Lopinavir, an anti-viral medication commonly used in people with HIV, has been shown to hold potential for preventing cervical cancer. Lopinavir is a protease inhibitor and a key component of Kaletra, a top-selling drug manufactured by Abbott Laboratories.

The preliminary study results were recently reported by BBC News online and Reuters Health, among other news channels.

Lopinavir attacks the human papilloma virus (HPV), which causes cervical cancer. Investigators Dr Ian Hampson and colleagues at the University of Manchester in Great Britain tested lopinavir against HPV, the most common cancer-causing strain of HPV.

"The drug works as a selective proteosome inhibitor,” Dr Hampson reportedly explained. “It allows cellular proteins that are detrimental to the virus to persist." Without lopinavir, HPV would normally remove these proteins from the cell.

Dr Hampson reportedly said he is confident that lopinavir will be effective against other HPV strains that are known to cause cervical cancer.

The investigators have suggested that lopinavir, taken orally, may be worth developing into an anti-cancer cream or pessary, based on early laboratory tests. Such a drug might offer women with precancerous lesions an alternative to surgery.

No clinical trials of lopinavir’s potential preventative role in cervical cancer have yet begun.

Because the drug is already FDA-approved to treat HIV, it is likely that a suitable preparation might be available to treat HPV in a few years.

According to BBC.com, Michael Carter of HIV organization Aidsmap said, "This latest finding is extremely welcome. Many HIV-positive individuals are infected with high-risk strains of HPV. Anal and cervical cancer caused by HPV is a real concern for people with HIV."

Mr Carter also noted that other research exists to support using some anti-HIV drugs to treat hepatitis B. People with HIV are more susceptible to HPV-related cancers and other diseases, because HIV compromises the immune system.

Hope rests on further studies, in a clinical setting. According to Dr Laura-Jane Armstrong of Cancer Research UK, the work by Dr Hampson and colleagues is "an interesting study, but the research has only been done on cells in the laboratory and we don’t yet know if it will work in humans.

"Currently, the best thing women can do to prevent cervical cancer developing is to go for regular cervical smear tests when invited."

Sources:
HIV drug stops cervical cancer in laboratory test, Reuters Health, August 25, 2006.
HIV drug can stop cervical cancer, BBC.com, August 24, 2006.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
November 17, 2008
Audience: Consumers, dermatologists, pharmacists, other healthcare professionals[Posted 11/17/2008] CSI USA Inc. and FDA informed...
November 12, 2008
Audience: Consumers, pediatricians, other healthcare professionals[Posted 11/12/2008] Johnson & Johnson, Merck Consumer...
November 12, 2008
Audience: Geriatricians, gynecologists, orthopedic surgeons, other healthcare professionals[Posted 11/12/2008] FDA issued an...
November 10, 2008
Audience: Pharmacists, other healthcare professionals, patients [Posted 11/10/2008] Ethex Corp and FDA notified healthcare...
More...
Latest Drug Information Updates

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

More...